SERTRALINE TABLETS, USP, Rx Only

/SERTRALINE TABLETS, USP, Rx Only
SERTRALINE TABLETS, USP, Rx Only2018-09-06T09:12:40+00:00

Prescription Drug Name:

SERTRALINE TABLETS, USP, Rx Only

ID:

89622982-f40f-4553-8506-a8fd3d6cfde7

Code:

34391-3

DESCRIPTION


id: e5d8768f-a80c-4c61-ae78-fb58f815f771
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride. The empirical formula C17H17NCl2•HCl is represented by the following structural formula: Sertraline hydrochloride, USP is a white crystalline powder that is slightly soluble in water and isopropyl alcohol, and sparingly soluble in ethanol. Sertraline hydrochloride is supplied for oral administration as white to off-white, capsule shaped, biconvex, film-coated tablets with a bisecting line on one side containing sertraline hydrochloride, USP equivalent to 25, 50 and 100 mg of sertraline and the following inactive ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polysorbate 80, propylene glycol, sodium starch glycolate, and titanium dioxide.

INDICATIONS AND USAGE


id: fe7a57cb-e850-451e-b0d7-1f32e9b8d3d8
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Major Depressive Disorder–Sertraline hydrochloride is indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY). Obsessive-Compulsive Disorder–Sertraline hydrochloride is indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride was established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Panic Disorder–Sertraline hydrochloride is indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride was established in three 10-12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Posttraumatic Stress Disorder (PTSD)–Sertraline hydrochloride is indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder (PMDD) – Sertraline hydrochloride is indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder – Sertraline hydrochloride is indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY).

CONTRAINDICATIONS


id: 234f58bf-869d-43ae-b846-3e0ecde8e348
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

The use of MAOIs intended to treat psychiatric disorders with sertraline tablets or within 14 days of stopping treatment with sertraline tablets is contraindicated because of an increased risk of serotonin syndrome. The use of sertraline tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION). Starting sertraline tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION). Concomitant use in patients taking pimozide is contraindicated (see PRECAUTIONS). Sertraline tablets are contraindicated in patients with a hypersensitivity to sertraline or any of the inactive ingredients in Sertraline tablets.

ADVERSE REACTIONS


id: f324d152-61bf-458f-9254-113654b11692
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

During its premarketing assessment, multiple doses of sertraline hydrochloride were administered to over 4000 adult subjects as of February 18, 2000. The conditions and duration of exposure to sertraline hydrochloride varied greatly, and included (in overlapping categories) clinical pharmacology studies, open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies, and studies for multiple indications, including major depressive disorder, OCD, panic disorder, PTSD, PMDD and social anxiety disorder. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories. In the tabulations that follow, a World Health Organization dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the over 4000 adult individuals exposed to multiple doses of sertraline hydrochloride who experienced a treatment-emergent adverse event of the type cited on at least one occasion while receiving sertraline hydrochloride. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is important to emphasize that events reported during therapy were not necessarily caused by it. The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the side effect incidence rate in the population studied. Incidence in Placebo-Controlled Trials- Table 2 enumerates the most common treatment-emergent adverse events associated with the use of sertraline hydrochloride (incidence of at least 5% for sertraline hydrochloride and at least twice that for placebo within at least one of the indications) for the treatment of adult patients with major depressive disorder/other*, OCD, panic disorder, PTSD, PMDD and social anxiety disorder in placebo-controlled clinical trials. Most patients in major depressive disorder/other*, OCD, panic disorder, PTSD and social anxiety disorder studies received doses of 50 to 200 mg/day. Patients in the PMDD study with daily dosing throughout the menstrual cycle received doses of 50 to 150 mg/day, and in the PMDD study with dosing during the luteal phase of the menstrual cycle received doses of 50 to 100 mg/day. Table 3 enumerates treatment-emergent adverse events that occurred in 2% or more of adult patients treated with sertraline hydrochloride and with incidence greater than placebo who participated in controlled clinical trials comparing sertraline hydrochloride with placebo in the treatment of major depressive disorder/other*, OCD, panic disorder, PTSD, PMDD and social anxiety disorder. Table 3 provides combined data for the pool of studies that are provided separately by indication in Table 2.

TABLE 2 MOST COMMON TREATMENT-EMERGENT ADVERSE EVENTS: INCIDENCE IN PLACEBO-CONTROLLED CLINICAL TRIALS
(
1
)Primarily ejaculatory delay. Denominator used was for male patients only (N=271 sertraline hydrochloride major depressive disorder/other*; N=271 placebo major depressive disorder/other*; N=296 sertraline hydrochloride OCD; N=219 placebo OCD; N=216 sertraline hydrochloride panic disorder; N=134 placebo panic disorder; N=130 sertraline hydrochloride PTSD; N=149 placebo PTSD; No male patients in PMDD studies; N=205 sertraline hydrochloride social anxiety disorder; N=153 placebo social anxiety disorder).
*Major depressive disorder and other premarketing controlled trials.
(
2
)The luteal phase and daily dosing PMDD trials were not designed for making direct comparisons between the two dosing regimens. Therefore, a comparison between the two dosing regimens of the PMDD trials of incidence rates shown in Table 2 should be avoided.
Percentage 
of 
Patients 
Reporting 
Event

Major 
Depressive


Disorder
/
Other
*

OCD

Panic 
Disorder

PTSD

Body 
System
/


Adverse 
Event

Sertraline


HCl 


(
N
=
861
)

Placebo


(
N
=
853
)

Sertraline


HCl 


(
N
=
533
)

Placebo


(
N
=
373
)

Sertraline


HCl


(
N
=
430
)

Placebo


(
N
=
275
)

Sertraline


HCl


(
N
=
374
)

Placebo


(
N
=
376
)

Autonomic 
Nervous


System 
Disorders

Ejaculation Failure(
1
)

7 <1 17 2 19 1 11 1
Mouth Dry 16 9 14 9 15 10 11 6
Sweating Increased 8 3 6 1 5 1 4 2
Center
.& 
Periph
.


Nerv

System 
Disorders

Somnolence 13 6 15 8 15 9 13 9
Tremor 11 3 8 1 5 1 5 1
Dizziness 12 7 17 9 10 10 8 5
General

Fatigue 11 8 14 10 11 6 10 5
Pain 1 2 3 1 3 3 4 6
Malaise <1 1 1 1 7 14 10 10
Gastrointestinal 
Disorders

Abdominal Pain 2 2 5 5 6 7 6 5
Anorexia 3 2 11 2 7 2 8 2
Constipation 8 6 6 4 7 3 3 3
Diarrhea/Loose Stools 18 9 24 10 20 9 24 15
Dyspepsia 6 3 10 4 10 8 6 6
Nausea 26 12 30 11 29 18 21 11
Psychiatric 
Disorders

Agitation 6 4 6 3 6 2 5 5
Insomnia 16 9 28 12 25 18 20 11
Libido Decreased 1 <1 11 2 7 1 7 2
PMDD


 
Daily 
Dosing

PMDD 
Luteal 
Phase 
Dosing

(


2


)

Social 
Anxiety


Disorder

BodySystem


Adverse 
Event

Sertraline


HCl 


(
N
=
121
)

Placebo


(
N
=
122
)

Sertraline


HCl


(
N
=
136
)

Placebo


(
N
=
127
)

Sertraline


HCl


(
N
=
344
)

Placebo


(
N
=
268
)

Autonomic 
Nervous 
System 
Disorders

Ejaculation Failure(
1
)

N/A N/A N/A N/A 14
Mouth Dry 6 3 10 3 12 4
Sweating Increased 6 <1 3 0 11 2
Center
.& 
Periph
.


Nerv
.
System 
Disorders

Somnolence 7 <1 2 0 9 6
Tremor 2 0 <1 <1 9 3
Dizziness 6 3 7 5 14 6
General

Fatigue 16 7 10 <1 12 6
Pain 6 <1 3 2 1 3
Malaise 9 5 7 5 8 3
Gastrointestinal 
Disorders

Abdominal Pain 7 <1 3 3 5 5
Anorexia 3 2 5 0 6 3
Constipation 2 3 1 2 5 3
Diarrhea/Loose Stools 13 3 13 7 21 8
Dyspepsia 7 2 7 3 13 5
Nausea 23 9 13 3 22 8
Psychiatric 
Disorders

Agitation 2 <1 1 0 4 2
Insomnia 17 11 12 10 25 10
Libido Decreased 11 2 4 2 9 3
TABLE 3 TREATMENT-EMERGENT ADVERSE EVENTS: INCIDENCE IN PLACEBO-CONTROLLED CLINICAL TRIALS Percentage of Patients Reporting Event Major Depressive Disorder/Other*, OCD, Panic Disorder, PTSD, PMDD and Social Anxiety Disorder combined
(
1
)Primarily ejaculatory delay. Denominator used was for male patients only (N=1118 sertraline hydrochloride; N=926 placebo).
*Major depressive disorder and other premarketing controlled trials.
*
*Included are events reported by at least 2% of patients taking sertraline hydrochloride except the following events, which had an incidence on placebo greater than or equal to sertraline hydrochloride: abdominal pain, back pain, flatulence, malaise, pain, pharyngitis, respiratory disorder, upper respiratory tract infection
Body 
System
/
Adverse 
Event
**

Sertraline


HCl


(
N
=
2799
)

Placebo


(
N
=
2394
)

Autonomic 
Nervous 
System 
Disorders

   Ejaculation Failure(
1
)

14 1
   Mouth Dry 14 8
   Sweating Increased 7 2
Center


Periph

Nerv

System 
Disorders

   Somnolence 13 7
   Dizziness 12 7
   Headache 25 23
   Paresthesia 2 1
   Tremor 8 2
Disorders 
of 
Skin 
and 
Appendages

   Rash 3 2
Gastrointestinal 
Disorders

   Anorexia 6 2
   Constipation 6 4
   Diarrhea/Loose Stools 20 10
   Dyspepsia 8 4
   Nausea 25 11
   Vomiting 4 2
General

   Fatigue 12 7
Psychiatric 
Disorders

   Agitation 5 3
   Anxiety 4 3
   Insomnia 21 11
   Libido Decreased 6 2
   Nervousness 5 4
Special 
Senses

   Vision Abnormal 3 2

DRUG ABUSE AND DEPENDENCE


id: e1cb834c-41b5-444d-a514-9a93832a65ab
displayName: DRUG ABUSE AND DEPENDENCE SECTION
FDA Article Code: 42227-9

Controlled Substance Class–Sertraline hydrochloride is not a controlled substance. Physical and Psychological Dependence–In a placebo-controlled, double-blind, randomized study of the comparative abuse liability of sertraline hydrochloride, alprazolam, and d-amphetamine in humans, sertraline hydrochloride did not produce the positive subjective effects indicative of abuse potential, such as euphoria or drug liking, that were observed with the other two drugs. Premarketing clinical experience with sertraline hydrochloride did not reveal any tendency for a withdrawal syndrome or any drug-seeking behavior. In animal studies sertraline hydrochloride does not demonstrate stimulant or barbiturate-like (depressant) abuse potential. As with any CNS active drug, however, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of sertraline hydrochloride misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

OVERDOSAGE


id: fca48a16-4460-45fe-9b41-a6963b8961ff
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

Human Experience–Of 1,027 cases of overdose involving sertraline hydrochloride worldwide, alone or with other drugs, there were 72 deaths (circa 1999). Among 634 overdoses in which sertraline hydrochloride was the only drug ingested, 8 resulted in fatal outcome, 75 completely recovered, and 27 patients experienced sequelae after overdosage to include alopecia, decreased libido, diarrhea, ejaculation disorder, fatigue, insomnia, somnolence and serotonin syndrome. The remaining 524 cases had an unknown outcome. The most common signs and symptoms associated with non-fatal sertraline hydrochloride overdosage were somnolence, vomiting, tachycardia, nausea, dizziness, agitation and tremor. The largest known ingestion was 13.5 grams in a patient who took sertraline hydrochloride alone and subsequently recovered. However, another patient who took 2.5 grams of sertraline hydrochloride alone experienced a fatal outcome. Other important adverse events reported with sertraline hydrochloride overdose (single or multiple drugs) include bradycardia, bundle branch block, coma, convulsions, delirium, hallucinations, hypertension, hypotension, manic reaction, pancreatitis, QT-interval prolongation, serotonin syndrome, stupor, syncope and Torsade de Pointes. Overdose Management–Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for sertraline are known. In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the Physicians’ Desk Reference
® (PDR®).

DOSAGE AND ADMINISTRATION


id: 5a595601-aa04-402a-9262-1feb22e1c888
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

Initial Treatment

HOW SUPPLIED


id: 1210a4ed-9031-4038-a6e3-c272703c424e
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Sertraline Tablets, USP are white to off-white capsule shaped, biconvex, film-coated tablets with a bisecting line on one side, containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline, are packaged in bottles. Sertraline 25 mg Tablets, USP: White to off-white, capsule shaped, biconvex, film-coated tablets with Torrent logo debossed on one side and ’25’ debossed with breakline separating 2 and 5 on the other side. NDC 13668-004-30                      Bottles of 30 NDC 13668-004-50                      Bottles of 50 NDC 13668-004-90                      Bottles of 90 NDC 13668-004-01                      Bottles of 100 NDC 13668-004-05                      Bottles of 500 NDC 13668-004-10                      Bottles of 1000 NDC 13668-004-09                      Bottles of 9990 Sertraline 50 mg Tablets, USP: White to off-white, capsule shaped, biconvex,  film-coated tablets with Torrent logo debossed on one side and ’50MG’ debossed with breakline separating 50 and MG on the other side. NDC 13668-005-30                      Bottles of 30 NDC 13668-005-50                      Bottles of 50 NDC 13668-005-90                      Bottles of 90 NDC 13668-005-01                      Bottles of 100 NDC 13668-005-05                      Bottles of 500 NDC 13668-005-10                      Bottles of 1000 NDC 13668-005-58                      Bottles of 4500 Sertraline 100 mg Tablets, USP: White to off-white, capsule shaped, biconvex, film-coated tablets with Torrent logo debossed on one side and ‘100MG’ debossed with breakline separating 100 and MG on the other side. NDC 13668-006-30                      Bottles of 30 NDC 13668-006-50                      Bottles of 50 NDC 13668-006-90                      Bottles of 90 NDC 13668-006-01                      Bottles of 100 NDC 13668-006-05                      Bottles of 500 NDC 13668-006-10                      Bottles of 1000 NDC 13668-006-13                      Bottles of 1300 NDC 13668-006-34                      Bottles of 2200 NDC 13668-006-74                      100 Unit dose Tablets Store at 20°-25°C (68°-77°F); excursions permitted to 15° – 30°C (59°- 86°F) [see USP Controlled Room Temperature].   Manufactured by: TORRENT PHARMACEUTICALS LTD., Indrad-382 721, INDIA. Manufactured for: TORRENT PHARMA INC., Basking Ridge, NJ 07920.    8047090                                                                        Revised September 2014

PRINCIPAL DISPLAY PANEL – 25 mg : Label


id: 44d5ed89-dd78-4342-9d9f-f1b33f676832
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

PRINCIPAL DISPLAY PANEL – 50 mg : Label


id: 80ceb206-fac3-4adb-8135-f70809a25a0e
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

PRINCIPAL DISPLAY PANEL – 100 mg : Label


id: 9530c9d2-fb68-487e-8651-39938b488b07
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4